Belite Bio (BLTE) Accumulated Expenses (2021 - 2025)

Belite Bio's Accumulated Expenses history runs 5 years deep, the most recent figure standing at $1.6 million for Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 129.02% year-over-year to $1.6 million in Q4 2025; TTM through Dec 2025 was $1.6 million, a 129.02% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 129.02% from the prior year.
• Accumulated Expenses fell to $1.6 million in Q4 2025 per BLTE's latest filing, from $7.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $7.8 million in Q3 2025 and bottomed at $56000.0 in Q4 2021.
• The 5-year median for Accumulated Expenses is $1.8 million (2022), against an average of $2.6 million.
• Across the five-year window, Accumulated Expenses soared 3303.57% in 2022 and slumped 78.86% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $56000.0 in 2021, then surged by 3303.57% to $1.9 million in 2022, then jumped by 74.45% to $3.3 million in 2023, then slumped by 78.86% to $703000.0 in 2024, then jumped by 129.02% to $1.6 million in 2025.
• Per Business Quant, the three latest BLTE Accumulated Expenses figures stand at $1.6 million (Q4 2025), $7.8 million (Q3 2025), and $703000.0 (Q4 2024).